17,261 trials
Bladder Cancer
Primary: Median Yield of Robot Assisted and Second Look Open Pelvic Lymph Node Dissection to Compare the Lymph Node Yield Achieved — 43; 4 Nodes (Node Yield)
Non-Small Cell Lung Cancer
Primary: Number of Participants Responding to the Vaccine — 6 Participants
Breast Cancer
Primary: Progression-free Survival (PFS) by the Investigator Using Modified Response Evaluation Criteria In Solid Tumors (RECIST) — 14.2; 9.2 Months
Depression
Primary: Hamilton Rating Scale for Depression (24 Question Version), a Standardized Assessment Tool for Measuring Severity of Depression Where 0 is the Minimum Score (no…
Cholangiocarcinoma of the Extrahepatic Bile Duct · Cholangiocarcinoma of the Gallbladder · Gastrointestinal Cancer
Primary: Number of Confirmed Tumor Responses. — 6; 0 participants
Influenza
Primary: Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against Two Strains of Influenza Disease. — 11.3; 9.7; 10.2; 8.8 Titer
Prostate Cancer
Primary: Percentage of Participants With Composite Response — 0.0; 0.0; 2.4 Percentage of participants
Prostatic Neoplasms
Primary: Progression-Free Survival (PFS) — 336.0; 232.0 Days — p=0.014
Emphysema · Alpha 1-antitrypsin Deficiency (AATD)
Primary: Subjects With Treatment-Emergent Adverse Events (TEAEs) — 23; 18 participants
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Maximum Tolerated Dose of MGd (Phase I) — 0; 0; 1 units on a scale
Inflammation · Crohn's Disease
Primary: Percentage of Subjects Achieving a 70-point Decline in CDAI Scores (Crohn's Disease Activity Index) Scores; — 40; 88 percentage of pts — p=0.009
Diabetes Mellitus, Type II · Diabetes Mellitus, Non Insulin Dependent
Primary: Change in HbA1c From Baseline to Week 12 — -0.22; -0.79; -0.76; -0.70 Percent — p=<0.001
Cervical Adenocarcinoma · Cervical Adenosquamous Carcinoma · Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Primary: Number of Subjects With Treatment-related Serious Adverse Events (SAEs) and Adverse Events (AEs) as Assessed by CTCAE v. 3.0 Criteria Within the First 90 Days From…
HIV · Cardiovascular Diseases · Atherosclerosis
Primary: Change in Flow-mediated Dilation of the Brachial Artery — -1.93; -1.06 absolute percentage — p=0.44
Congenital Amegakaryocytic Thrombocytopenia · Diamond-blackfan Anemia · Leukemia
Primary: Number of Participants Achieving Durable Engraftment (Presence of Donor Cells) at 6 Weeks Post Transplantation — 31 participants